Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally.
New deal enables Oxford BioTherapeutics (OBT) to evaluate OBT076 with a checkpoint inhibitor (CPI) in both CPI-naïve and resistant patientsOBT076 has previously shown preliminary signs of clinical
Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.